[en] Indoleamine 2,3-dioxygenase (IDO) is an important new therapeutic target for the treatment of cancer. With the aim of discovering novel IDO inhibitors, a virtual screen was undertaken and led to the discovery of the keto-indole derivative 1a endowed with an inhibitory potency in the micromolar range. Detailed kinetics were performed and revealed an uncompetitive inhibition profile. Preliminary SARs were drawn in this series and corroborated the putative binding orientation as suggested by docking.
C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van den Eynde Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 9 2003 1269 1274 (Pubitemid 37279849)
S.A. Rafice, N. Chauhan, I. Efimov, J. Basran, and E.L. Raven Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase Biochem. Soc. Trans. 37 2009 408 412
M. Sono, M.P. Roach, E.D. Coulter, and J.H. Dawson Heme-containing oxygenases Chem. Rev. 96 1996 2841 2888
P. Hwu, M.X. Du, R. Lapointe, M. Do, M.W. Taylor, and H.A. Young Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation J. Immunol. 164 2000 3596 3599 (Pubitemid 30169812)
A.L. Mellor, and D.H. Munn IDO expression by dendritic cells: tolerance and tryptophan catabolism Nat. Rev. Immunol. 4 2004 762 774 (Pubitemid 39336293)
D.H. Munn, M. Zhou, J.T. Attwood, I. Bondarev, S.J. Conway, B. Marshall, C. Brown, and A.L. Mellor Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 1998 1191 1193 (Pubitemid 28406294)
Y. Kudo, and C.A. Boyd Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection Biochim. Biophys. Acta 1500 2000 119 124 (Pubitemid 29525405)
G. Brandacher, A. Perathoner, R. Ladurner, S. Schneeberger, P. Obrist, C. Winkler, E.R. Werner, G. Werner-Felmayer, H.G. Weiss, G. Gobel, R. Margreiter, A. Konigsrainer, D. Fuchs, and A. Amberger Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells Clin. Cancer Res. 12 2006 1144 1151 (Pubitemid 43342502)
A. Okamoto, T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, R. Kawaguchi, S. Isonishi, T. Tanaka, and M. Urashima Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells Clin. Cancer Res. 11 2005 6030 6039 (Pubitemid 41170335)
B.S. Leung, L.E. Stout, E.G. Shaskan, and R.M. Thompson Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells Cancer Lett. 66 1992 77 81
A.J. Muller, J.B. DuHadaway, P.S. Donover, E. Sutanto-Ward, and G.C. Prendergast Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat. Med. 11 2005 312 319 (Pubitemid 40460560)
A.J. Muller, W.P. Malachowski, and G.C. Prendergast Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors Expert Opin. Ther. Targets 9 2005 831 849 (Pubitemid 41131682)
A.J. Muller, and G.C. Prendergast Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 65 2005 8065 8068 (Pubitemid 41330565)
A.J. Muller, and G.C. Prendergast Indoleamine 2,3-dioxygenase in immune suppression and cancer Curr. Cancer Drug Targets 7 2007 31 40 (Pubitemid 46345506)
A. Macchiarulo, E. Camaioni, R. Nuti, and R. Pellicciari Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease Amino Acids 37 2009 219 229
S.G. Cady, and M. Sono 1-Methyl-dl-tryptophan, beta-(3-benzofuranyl)-dl- alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-dl- alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase Arch. Biochem. Biophys. 291 1991 326 333
N. Eguchi, Y. Watanabe, K. Kawanishi, Y. Hashimoto, and O. Hayaishi Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives Arch. Biochem. Biophys. 232 1984 602 609
H.C. Brastianos, E. Vottero, B.O. Patrick, R. Van Soest, T. Matainaho, A.G. Mauk, and R.J. Andersen Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua J. Am. Chem. Soc. 128 2006 16046 16047 (Pubitemid 44936592)
A. Pereira, E. Vottero, M. Roberge, A.G. Mauk, and R.J. Andersen Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata J. Nat. Prod. 69 2006 1496 1499 (Pubitemid 44899767)
T. Banerjee, J.B. Duhadaway, P. Gaspari, E. Sutanto-Ward, D.H. Munn, A.L. Mellor, W.P. Malachowski, G.C. Prendergast, and A.J. Muller A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase Oncogene 27 2008 2851 2857 (Pubitemid 351620442)
P. Gaspari, T. Banerjee, W.P. Malachowski, A.J. Muller, G.C. Prendergast, J. DuHadaway, S. Bennett, and A.M. Donovan Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 49 2006 684 692 (Pubitemid 43157498)
G. Carr, M.K. Chung, A.G. Mauk, and R.J. Andersen Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A J. Med. Chem. 51 2008 2634 2637 (Pubitemid 351620784)
S. Kumar, W.P. Malachowski, J.B. DuHadaway, J.M. LaLonde, P.J. Carroll, D. Jaller, R. Metz, G.C. Prendergast, and A.J. Muller Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors J. Med. Chem. 51 2008 1706 1718 (Pubitemid 351438852)
M. Sono, and S.G. Cady Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands Biochemistry 28 1989 5392 5399 (Pubitemid 19175747)
H. Sugimoto, S. Oda, T. Otsuki, T. Hino, T. Yoshida, and Y. Shiro Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase Proc. Natl. Acad. Sci. U S A 103 2006 2611 2616
S. Kumar, D. Jaller, B. Patel, J.M. LaLonde, J.B. DuHadaway, W.P. Malachowski, G.C. Prendergast, and A.J. Muller Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase J. Med. Chem. 51 2008 4968 4977
G. Carr, W. Tay, H. Bottriell, S.K. Andersen, A.G. Mauk, and R.J. Andersen Plectosphaeroic acids A, B, and C, indoleamine 2,3-dioxygenase inhibitors produced in culture by a marine isolate of the fungus Plectosphaerella cucumerina Org. Lett. 11 2009 2996 2999
E.W. Yue, B. Douty, B. Wayland, M. Bower, X. Liu, L. Leffet, Q. Wang, K.J. Bowman, M.J. Hansbury, C. Liu, M. Wei, Y. Li, R. Wynn, T.C. Burn, H.K. Koblish, J.S. Fridman, B. Metcalf, P.A. Scherle, and A.P. Combs Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 52 2009 7364 7367
U.F. Rohrig, L. Awad, A. Grosdidier, P. Larrieu, V. Stroobant, D. Colau, V. Cerundolo, A.J. Simpson, P. Vogel, B.J. Van den Eynde, V. Zoete, and O. Michielin Rational design of indoleamine 2,3-dioxygenase inhibitors J. Med. Chem. 53 2010 1172 1189
Sybyl 8.0, Tripos Inc., in, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.
W.L. Delano, The PyMOL Molecular Graphics System on World Wide Web. http://pymol.sourceforge.net/ (accessed 08.02.11).
B.K. Shoichet Virtual screening of chemical libraries Nature 432 2004 862 865 (Pubitemid 40037142)
J.J. Irwin, and B.K. Shoichet ZINC-a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 45 2005 177 182 (Pubitemid 40736970)
S.J. Teague, A.M. Davis, P.D. Leeson, and T. Oprea The design of leadlike combinatorial libraries Angew. Chem. Int. Ed. Engl. 38 1999 3743 3748 (Pubitemid 30022004)
R.D. Clark, A. Strizhev, J.M. Leonard, J.F. Blake, and J.B. Matthew Consensus scoring for ligand/protein interactions J. Mol. Graph Model. 20 2002 281 295 (Pubitemid 34017546)
G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748 (Pubitemid 27170693)
C. Lu, Y. Lin, and S.R. Yeh Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase Biochemistry 49 2010 5028 5034
E. Dolušić, P. Larrieu, S. Blanc, F. Sapunaric, B. Norberg, L. Moineaux, D. Colette, V. Stroobant, L. Pilotte, D. Colau, T. Ferain, G. Fraser, M. Galeni, J.M. Frere, B. Masereel, B. Van den Eynde, J. Wouters, R. Frederick, Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors, Bioorg. Med. Chem. 19 (2011) 1550-1561.
R.G. Sundberg, J.G. Luis, R.L. Parton, S. Schreiber, P.C. Srinivasan, P. Lamb, P. Forcier, and R.B. Bryan Chloroacetamide photocyclization of indole derivatives. synthesis, stereochemistry, and crystal structure of 3,7-methano-3-azacycloundecino5[,4-blindole (deethylquebrachamine) derivatives J. Org. Chem. 23 1978 4859 4865 (Pubitemid 9115623)
O. Takikawa, T. Kuroiwa, F. Yamazaki, and R. Kido Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity J. Biol. Chem. 263 1988 2041 2048 (Pubitemid 18052167)
S. Oda, H. Sugimoto, T. Yoshida, and Y. Shiro Crystallization and preliminary crystallographic studies of human indoleamine 2,3-dioxygenase Acta Crystallogr. Sect. F Struct. Biol. Cryst Commun. 62 2006 221 223 (Pubitemid 43885317)
E. Alegre, A.S. Lopez, and A. Gonzalez Tryptophan metabolites interfere with the Ehrlich reaction used for the measurement of kynurenine Anal. Biochem. 339 2005 188 189 (Pubitemid 40342697)
